SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
April 21, 2023
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Israeli Cannabis Technology Company BYND Cannasoft Enterprises Files US Provisional Patent Application and Full Scale PCT Application for Its EZ-G Device
January 17, 2023
Ryan Allway January 17th, 2023 News, Top News The new full scale PCT application for the EZ-G device, comprised of a structure and one or more moving and vibrating elements, will utilize Artificial Intelligence (AI) to send data about learned sexual preferences to the cloud to heighten arousal, and... Read more
Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
September 22, 2022
Ryan Allway September 22nd, 2022 Psychedelics, Top News Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd. VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “Company“), a biotech... Read more
Cannabis Global Provides Patent Applications Update – Company Files Response to US Patent Office Relative to Cannabis Nanoparticle Application
August 16, 2022
Ryan Allway August 16th, 2022 News, Top News LOS ANGELES, CA / ACCESSWIRE / August 16, 2022 / Cannabis Global, Inc. (OTC PINK:CBGL), Cannabis Global, Inc., a licensed Los Angeles-based manufacturer and distributor in the cannabis sector, today provides an update concerning the Company’s patent applications, especially relating to its... Read more
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
Biotechnology July 19, 2022
Ryan Allway July 19th, 2022 Psychedelics, Top News Company aims to increase health equity by developing more accessible treatment modalities better suited for existing healthcare infrastructure DENVER, July 19, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology... Read more
NeonMind Files New Provisional Patent Application Covering Novel Mechanism of Weight Loss
March 22, 2022
Ryan Allway March 22nd, 2022 News, Top News OAKVILLE, ON / ACCESSWIRE / March 22, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today it... Read more
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
December 15, 2021
Ryan Allway December 15th, 2021 Psychedelics VANCOUVER, BC, Dec. 15, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe:... Read more
